Myriad Genetics - Timeline

Timeline

• 1991 - BRCA1 was linked to chromosome 17 by UC Berkeley scientists
• 1991 - Myriad Genetics was founded by Dr. Walter Gilbert, Mark Skolnick, Kevin Kimberlin and Peter Meldrum
• 1994 - BRCA1 was cloned at the University of Utah in Mark Skolnick’s lab and published by 40 collaborators
• 1994 - First BRCA1 U.S. patent was filed by the University of Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics
• 1994/1995 - Development of process and laboratory to perform high throughput sequencing by Myriad
• 1995 - BRCA2 was resequenced based on unpublished information at the Myriad facility and the University of Utah by Mark Skolnick and collaborators
• 1995 - First BRCA2 patent filed in the U.S. by the University of Utah and other institutions
• 1996 - Myriad launched BRACAnalysis, a predictive medicine product for hereditary breast and ovarian cancer
• 1997 - First BRCA1 patent was granted in the U.S. to the University of Utah, NIEHS and Myriad Genetics
• 1998 - First BRCA2 patent was granted in the U.S. to the University of Utah, NIEHS and Myriad Genetics
• 2000 - Myriad launched COLARIS, a predictive medicine product for hereditary colorectal and uterine cancer
• 2002 - Myriad launched COLARIS AP, a predictive medicine product for adenomatous polyposis colon cancer syndromes
• 2002 - Myriad launched MELARIS, a predictive medicine product for hereditary melanoma
• 2007 - Myriad launched TheraGuide 5-FU, a personalized medicine product to predict toxicity to 5-FU-based chemotherapy
• 2008 - Myriad launched PREZEON, a personalized medicine product to assess the status of the PTEN gene
• 2009 - Myriad launched OnDose, a personalized medicine product to measure a patient’s exposure to 5-FU chemotherapy
• 2010 - Myriad launched PANEXIA, a predictive medicine product for hereditary pancreatic and related cancers

In July, 2009, the spin off, Myriad Pharmaceuticals, was completed. Myriad Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of therapeutic products.